Insmed Incorporated (NASDAQ:INSM) Shares Acquired by Atria Investments Inc

Atria Investments Inc boosted its holdings in Insmed Incorporated (NASDAQ:INSM) by 61.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,985 shares of the biopharmaceutical company’s stock after acquiring an additional 1,902 shares during the quarter. Atria Investments Inc’s holdings in Insmed were worth $364,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of Insmed by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 14,509,235 shares of the biopharmaceutical company’s stock valued at $393,636,000 after purchasing an additional 383,714 shares during the period. Darwin Global Management Ltd. bought a new stake in shares of Insmed during the second quarter worth $237,076,000. Principal Financial Group Inc. boosted its holdings in Insmed by 12.9% in the third quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company’s stock valued at $136,648,000 after acquiring an additional 214,130 shares during the last quarter. Clearbridge Investments LLC boosted its holdings in Insmed by 76.8% during the second quarter. Clearbridge Investments LLC now owns 1,644,948 shares of the biopharmaceutical company’s stock worth $110,212,000 after buying an additional 714,539 shares during the last quarter. Finally, Capital International Investors bought a new position in Insmed during the first quarter worth about $43,973,000.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on INSM. TD Cowen raised their price target on Insmed from $75.00 to $98.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Cantor Fitzgerald reissued an “overweight” rating on shares of Insmed in a research report on Monday, September 9th. HC Wainwright reissued a “buy” rating and issued a $90.00 target price on shares of Insmed in a research report on Friday, November 1st. StockNews.com lowered Insmed from a “hold” rating to a “sell” rating in a research report on Friday, August 9th. Finally, Bank of America lifted their target price on Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a research report on Wednesday, October 9th. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $83.07.

Insider Buying and Selling at Insmed

In other Insmed news, insider Martina M.D. Flammer sold 13,436 shares of the stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $74.92, for a total value of $1,006,625.12. Following the transaction, the insider now owns 106,134 shares in the company, valued at approximately $7,951,559.28. This represents a 11.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total value of $2,686,612.50. Following the completion of the sale, the insider now directly owns 100,100 shares of the company’s stock, valued at approximately $7,157,150. This trade represents a 27.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 78,882 shares of company stock worth $5,765,446. Insiders own 4.60% of the company’s stock.

Insmed Price Performance

Insmed stock opened at $73.81 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $80.53. The stock has a market capitalization of $13.20 billion, a P/E ratio of -13.09 and a beta of 1.12. The stock has a fifty day moving average of $72.07 and a 200-day moving average of $65.65.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The business had revenue of $93.40 million during the quarter, compared to analyst estimates of $93.36 million. During the same period in the previous year, the firm posted ($1.10) earnings per share. The firm’s quarterly revenue was up 18.1% on a year-over-year basis. On average, sell-side analysts expect that Insmed Incorporated will post -5.42 earnings per share for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.